List of Excipients in Branded Drug VIJOICE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	VIJOICE	alpelisib	0078-1021	CELLULOSE, MICROCRYSTALLINE	2029-04-05
Novartis Pharmaceuticals Corporation	VIJOICE	alpelisib	0078-1021	FERRIC OXIDE RED	2029-04-05
Novartis Pharmaceuticals Corporation	VIJOICE	alpelisib	0078-1021	FERRIC OXIDE YELLOW	2029-04-05

VIJOICE Excipient Strategy and Commercial Opportunities for Alpelisib

Last updated: August 21, 2026

VIJOICE is an oral alpelisib product developed by Novartis for adults and children aged 2 years and older with severe manifestations of PIK3CA-related overgrowth spectrum, or PROS. Its formulation strategy is commercially important because the target population includes young children who may have difficulty swallowing tablets and require flexible dosing. VIJOICE is supplied as film-coated tablets and granules for oral suspension, creating opportunities in pediatric excipients, taste masking, dose flexibility, stability, and differentiated generic development. [1]

What is VIJOICE and which dosage forms does it use?

VIJOICE contains alpelisib, a selective inhibitor of phosphatidylinositol 3-kinase alpha, or PI3K-alpha. The FDA approved VIJOICE on April 5, 2022, under the accelerated approval pathway for adults and pediatric patients aged 2 years and older with severe manifestations of PROS requiring systemic therapy. [1]

Product attribute	VIJOICE
Active ingredient	Alpelisib
Sponsor	Novartis Pharmaceuticals Corp.
FDA application	NDA 215039
Initial FDA approval	April 5, 2022
Indication	Severe manifestations of PIK3CA-related overgrowth spectrum
Patient population	Adults and children aged 2 years and older
Dosage forms	Tablets and granules for oral suspension
Tablet strengths	50 mg, 125 mg, 200 mg
Pediatric administration	Granules dispersed in water for oral suspension
Administration	Once daily, with food
Regulatory pathway	Accelerated approval

VIJOICE is distinct from PIQRAY, another Novartis alpelisib product approved for PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. The two products contain the same active ingredient but address different diseases, age groups, dosing requirements, and commercial channels.

What excipients are used in VIJOICE tablets and granules?

The FDA prescribing information identifies a conventional immediate-release solid oral excipient system for VIJOICE tablets and a separate granule platform for pediatric administration. [1]

VIJOICE tablet excipient strategy

The tablet formulation uses excipients associated with direct compression or conventional tablet manufacturing, film coating, disintegration, lubrication, and product appearance. The label identifies excipients including lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, hypromellose, talc, titanium dioxide, and iron oxides. [1]

Excipient function	VIJOICE formulation role
Lactose monohydrate	Diluent and tablet mass builder
Microcrystalline cellulose	Diluent and compression aid
Sodium starch glycolate	Superdisintegrant
Magnesium stearate	Lubricant
Hypromellose	Film-coating polymer
Talc	Coating and anti-tacking agent
Titanium dioxide	Opacifier and color modifier
Iron oxides	Tablet-color differentiation

The tablet platform is operationally efficient because it uses widely available pharmaceutical-grade materials. It also supports multiple strengths without requiring a separate modified-release system. The principal formulation risks are dose uniformity across strengths, dissolution consistency, moisture control, and maintenance of alpelisib stability during granulation, compression, coating, and storage.

VIJOICE granule excipient strategy

The granules are intended for dispersion in water before administration. The product is supplied in single-dose packets, which supports dose accuracy and limits the need for caregivers to split tablets or manipulate solid dosage forms. The granule platform is particularly relevant for children with dysphagia, developmental limitations, or anatomy affected by PROS.

The granule formulation uses excipients that support powder flow, dose uniformity, dispersion, and oral administration. The FDA labeling identifies lactose monohydrate, microcrystalline cellulose, crospovidone, and sodium lauryl sulfate among the inactive ingredients for the granules. [1]

Granule requirement	Formulation objective
Rapid wetting	Permit dispersion in a small volume of water
Uniform particle distribution	Reduce dose variability in the administered suspension
Fast disintegration	Release alpelisib from granules
Acceptable mouthfeel	Improve pediatric administration
Chemical stability	Limit degradation during shelf life
Low segregation tendency	Preserve content uniformity in packets
Controlled dusting	Improve manufacturing and caregiver handling

The granule strategy is more technically demanding than a standard tablet. Particle-size distribution, electrostatic behavior, wetting, sedimentation, redispersion, and residue on the administration vessel can affect the delivered dose. A pediatric product must also account for taste, odor, suspension texture, and the volume of water used by caregivers.

Why are pediatric excipients commercially important for VIJOICE?

Pediatric excipient selection is a central commercial issue because children may receive alpelisib for prolonged periods and may have limited tolerance for bitter or irritating oral medicines. The FDA has recognized the need for age-appropriate dosage forms and careful excipient selection in pediatric drug development. [2]

Alpelisib is a potent small molecule administered at relatively low pediatric doses compared with conventional high-dose oral drugs. This creates a need for:

• High content uniformity at low fill weights.
• Reliable dispersion from individual packets.
• Minimal sedimentation during administration.
• Low residual volume in cups, syringes, or feeding devices.
• Acceptable taste without compromising drug release.
• Excipients with established pediatric safety profiles.
• Packaging that protects against moisture and powder loss.

Potential commercial value exists in excipients and processing technologies that improve the granule experience without changing the active ingredient. Relevant technologies include spray-congealed particles, polymeric taste-masking coatings, lipid-based barriers, ion-exchange resins, co-processed diluents, and low-moisture granulation systems.

A reformulated pediatric product would need to preserve bioavailability and demonstrate acceptable pharmaceutical equivalence or clinical comparability, depending on the regulatory pathway. Taste masking that delays dissolution or changes exposure would create a material development risk.

What formulation patents may protect VIJOICE or competing alpelisib products?

Alpelisib has composition-of-matter, therapeutic-use, formulation, and manufacturing patent categories. The most valuable patent rights generally relate to the active molecule and its use in defined patient populations. Excipients can create additional protection when they are linked to a specific dosage form, stability profile, particle engineering process, reconstitution method, or administration protocol.

Patent categories relevant to VIJOICE

Patent category	Potential scope	Commercial significance
Composition of matter	Alpelisib molecule and pharmaceutically acceptable forms	Primary barrier to generic entry
Therapeutic use	PI3K-alpha inhibition in PROS or PIK3CA-driven disease	Can restrict indication-specific labeling
Solid-state form	Polymorphs, salts, solvates, crystalline forms	May constrain API sourcing
Tablet formulation	Excipients, dissolution, coating, stability	May create secondary protection
Granule formulation	Particle size, dispersion, taste masking, dose uniformity	Particularly relevant to pediatric competition
Manufacturing process	Crystallization, granulation, milling, coating	Can complicate non-infringing manufacture
Packaging	Moisture-protective packets and administration systems	Usually narrower but commercially useful

The commercial strength of an excipient patent depends on claim breadth. A patent that claims only a named excipient at a narrow concentration range may be easier to design around than a patent covering the functional performance of a granule system, such as rapid dispersion, low sedimentation, or a defined dissolution profile.

What is the FDA regulatory status and Orange Book position for VIJOICE?

VIJOICE received accelerated approval based on a response assessment in patients with PROS. Continued approval is contingent on verification of clinical benefit in confirmatory studies. [1]

The regulatory distinction between VIJOICE and PIQRAY is important. Alpelisib was already approved as PIQRAY before VIJOICE entered the market. VIJOICE therefore did not represent the first approval of alpelisib as an active ingredient. This limits the relevance of new chemical entity exclusivity to the VIJOICE approval itself.

Regulatory issue	VIJOICE implication
New chemical entity exclusivity	Not created by the 2022 VIJOICE approval because alpelisib was previously approved
Accelerated approval	Yes
Orphan-drug considerations	Potentially relevant to the PROS indication if the applicable designation and exclusivity requirements are satisfied
Pediatric exclusivity	No separate VIJOICE pediatric exclusivity should be assumed solely from pediatric labeling
Orange Book	Product-specific patent and exclusivity status must be assessed against the current FDA listing
Generic pathway	505(j) may be possible for tablets; granules may require more complex equivalence work

The Orange Book analysis should distinguish patents listed for PIQRAY from patents listed for VIJOICE. A patent covering alpelisib generally may have broader relevance than a patent limited to breast-cancer treatment, but listing, enforceability, claim scope, and regulatory-use-code limitations remain separate questions. [3]

When does VIJOICE lose exclusivity?

There is no single VIJOICE exclusivity date that determines generic entry. Market entry will depend on the interaction of patent expiration, listed method-of-use claims, regulatory exclusivity, pediatric requirements, and the dosage form targeted by a competitor.

The key timing considerations are:

1. Alpelisib composition-of-matter rights may control early entry if they remain enforceable.
2. Method-of-use patents may affect labeling for PROS even if a generic can launch with a narrower label.
3. Formulation patents may be more important for granules than for conventional tablets.
4. A tablet applicant may have a different risk profile from a granule applicant.
5. Patent settlements may permit entry before the latest listed patent expires.

The original alpelisib patent family is associated with Novartis and its predecessor organizations. Exact expiration dates should be determined from the relevant U.S. patent family, patent-term adjustment, terminal disclaimers, Orange Book listings, and any patent-term extension. A fixed date based only on the earliest priority filing would not be reliable.

What generic entry risks exist for VIJOICE?

Tablet generic entry

A tablet competitor could pursue an abbreviated new drug application if it can demonstrate pharmaceutical equivalence and bioequivalence. The primary technical issues would include:

• Matching the approved strengths.
• Demonstrating dissolution across relevant conditions.
• Controlling polymorphic form and particle size.
• Avoiding excipient incompatibility.
• Establishing bioequivalence with food.
• Addressing listed composition or method patents through Paragraph IV certification.

The tablet route may be more accessible than the granule route because conventional tablets use widely available excipients and established manufacturing processes.

Granule generic entry

Granules for oral suspension create greater development complexity. A competitor would need to address:

• Packet fill-weight accuracy.
• Reconstitution instructions.
• Sedimentation and redispersion.
• Dose recovery from the container.
• Taste and mouthfeel.
• Administration through oral syringes or feeding devices.
• Stability after dispersion.
• Comparative bioavailability.

A generic granule product may be pharmaceutically equivalent without duplicating every excipient, but a substantially different taste-masking or dispersion system could generate clinical or bioequivalence issues.

Which companies are positioned to challenge VIJOICE?

The most likely challengers are established generic manufacturers with oncology portfolios, pediatric oral-dose capabilities, and experience with complex dosage forms. Potential categories include:

Challenger type	Likely target
Large generic manufacturers	Alpelisib tablets
Specialty oncology generics companies	Tablets and indication-limited products
Complex generics developers	Granules and pediatric formulations
CDMOs with oral-dose platforms	Contract development or licensed products
Pediatric formulation companies	Taste-masked granules or suspension systems

A first generic entrant would likely prioritize tablets because of lower development and manufacturing complexity. A second-wave competitor could pursue granules if the PROS market expands and the reference product demonstrates durable pediatric demand.

How strong is the VIJOICE patent estate?

The estate is strongest where several layers overlap:

• Active-ingredient protection.
• PROS-specific method-of-use claims.
• Pediatric granule claims.
• Manufacturing controls for alpelisib particle properties.
• Stability and packaging claims.

It is weaker where protection depends on narrow excipient combinations that can be substituted without changing performance. Excipients themselves are rarely durable barriers because lactose, microcrystalline cellulose, crospovidone, hypromellose, and related materials are widely available and can often be replaced.

The strongest formulation strategy would claim measurable product attributes rather than only a list of ingredients. Examples include a defined dissolution range, dispersion time, sedimentation rate, particle-size distribution, impurity profile, or stability threshold.

What commercial opportunities exist in VIJOICE excipients?

Co-processed excipients

Co-processed diluents and binders could improve flow, compressibility, and low-dose content uniformity in alpelisib tablets. Products that reduce segregation during blending may have value for smaller tablet strengths and high-potency manufacturing.

Pediatric taste masking

Taste-masked alpelisib granules represent the most differentiated opportunity. Suitable platforms could include polymer-coated particles, lipid barriers, ion-exchange systems, or multiparticulate technologies. The formulation must release alpelisib rapidly after administration and avoid food-dependent exposure changes.

Single-dose packaging

Moisture-resistant sachets, high-barrier laminates, and unit-dose systems can improve stability and reduce caregiver dosing errors. Packaging suppliers that can integrate dose identification, child-resistant features, and low-residue dispensing may obtain a role in branded or generic products.

Feeding-tube compatibility

Children with PROS may require administration through enteral feeding devices. A formulation that disperses consistently, does not clog tubes, and provides high dose recovery could support a differentiated product or a supplemental application.

Manufacturing services

CDMOs with high-potency containment, low-dose granulation, multiparticulate coating, and unit-dose packaging capabilities are positioned to support alpelisib lifecycle development. The relevant capabilities are more specialized than standard tablet compression.

505(b)(2) reformulation opportunities

A 505(b)(2) product could pursue a differentiated granule, suspension, sachet, or administration system if it can establish a meaningful clinical or pharmaceutical advantage. Potential claims could involve improved pediatric acceptability, reduced administration burden, or better dose recovery. The commercial case would depend on reimbursement, patent protection, and whether the reformulation supports a new label or market exclusivity.

How does VIJOICE compare with PIQRAY?

Factor	VIJOICE	PIQRAY
Active ingredient	Alpelisib	Alpelisib
Primary disease	PROS	PIK3CA-mutated advanced breast cancer
Main population	Adults and children aged 2 years and older	Adults
Formulation emphasis	Tablets and pediatric granules	Tablets
Dosing flexibility	Higher need because of pediatric use	Primarily adult fixed-strength dosing
Excipient opportunity	Pediatric dispersion, taste masking, low-dose uniformity	Tablet manufacturability and stability
Generic risk	Indication and granule complexity	Conventional oncology-tablet competition
Patent focus	PROS use, granules, pediatric administration	Composition, oncology use, tablet formulation

PIQRAY provides a commercial and regulatory precedent for alpelisib exposure, food effects, safety monitoring, and manufacturing. VIJOICE expands the value of the molecule into a rare pediatric disease market where dosage-form performance can be as important as the active ingredient.

What licensing and partnering opportunities exist?

Licensing opportunities are most credible in four areas:

1. Pediatric formulation technology that improves taste, dispersion, or feeding-tube delivery.
2. Co-developed generic or follow-on products using differentiated granules.
3. CDMO partnerships for high-potency alpelisib manufacture and unit-dose packaging.
4. Regional commercialization agreements for rare-disease products.

A partner with an established pediatric specialty sales force may be more valuable than a conventional primary-care generic company. PROS treatment is concentrated among specialist centers, geneticists, surgeons, and pediatric oncology or vascular-anomaly teams. Commercial access depends on diagnosis, referral networks, and reimbursement support.

What revenue exposure does VIJOICE create?

VIJOICE addresses a smaller population than PIQRAY but has a higher dosage-form burden and potentially longer treatment duration for some patients. Revenue depends on:

• Number of diagnosed PROS patients.
• Severity requiring systemic therapy.
• Pediatric diagnosis and referral rates.
• Duration of treatment.
• Reimbursement for an orphan or rare-disease product.
• Availability of tablet versus granule presentations.
• Generic entry by indication and dosage form.

The commercial value of excipient innovation is therefore unlikely to come from excipient cost reduction alone. The larger opportunity is protecting or enabling premium positioning through easier pediatric administration, reduced dosing errors, improved adherence, and reliable supply.

Key Takeaways

• VIJOICE is an alpelisib product for severe PROS, with tablets and granules for oral suspension.
• The granule dosage form is the main excipient-driven differentiation.
• Lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, crospovidone, hypromellose, magnesium stearate, talc, titanium dioxide, iron oxides, and sodium lauryl sulfate support conventional tablet and pediatric granule functions.
• Pediatric taste masking, rapid dispersion, low-dose uniformity, feeding-tube compatibility, and moisture-protective packaging are the strongest commercial opportunities.
• Tablet generics are likely to be technically more accessible than granule generics.
• Alpelisib’s prior approval as PIQRAY limits the relevance of new chemical entity exclusivity for VIJOICE.
• Patent strength depends on active-ingredient, PROS-use, formulation, manufacturing, and packaging claims operating together.
• A differentiated 505(b)(2) granule or administration system could create value if it demonstrates a meaningful pediatric advantage.

FAQs

Can VIJOICE excipients be freely substituted in a generic product?

No. A generic applicant may use different inactive ingredients, but it must demonstrate pharmaceutical equivalence, bioequivalence, stability, and acceptable performance. Differences in taste, dispersion, dose recovery, or gastrointestinal exposure can complicate approval.

Is VIJOICE a biologic with biosimilar risk?

No. VIJOICE contains alpelisib, a chemically synthesized small molecule. Competition would generally involve generic or hybrid drug applications, not biosimilar applications.

Does VIJOICE require a taste-masking patent?

Not necessarily, but taste masking can support meaningful differentiation. A patent is more commercially valuable when it covers a defined composition together with measurable performance, such as dispersion time, dissolution, stability, or improved palatability.

Could a generic launch tablets while excluding the PROS indication?

Potentially. A generic applicant may pursue a limited label if patent claims or regulatory restrictions cover a method of use. The feasibility depends on the scope of listed patents, FDA labeling requirements, and whether the omitted indication can be carved out effectively.

What is the highest-value excipient opportunity for alpelisib?

The highest-value opportunity is a pediatric granule platform that combines strong taste masking, rapid dispersion, low sedimentation, high dose recovery, and compatibility with oral syringes or feeding tubes.

References

1. U.S. Food and Drug Administration. (2022). VIJOICE (alpelisib) prescribing information. Novartis Pharmaceuticals Corporation.
2. U.S. Food and Drug Administration. (2022). E11(R1) addendum to ICH E11: Clinical investigation of medicinal products in the pediatric population.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.